Dysregulation of the NLRP3 Inflammasome in Diabetic Retinopathy and Potential Therapeutic Targets

References

• Bourne RRA, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013;1:e339–49. doi:https://doi.org/10.1016/S2214-109X(13)70113-X.
   PubMed Web of Science ®Google Scholar
• Homme RP, Singh M, Majumder A, et al. Remodeling of retinal architecture in diabetic retinopathy: disruption of ocular physiology and visual functions by inflammatory gene products and pyroptosis. Front Physiol. 2018;9:1268. doi:https://doi.org/10.3389/fphys.2018.01268.
   PubMed Web of Science ®Google Scholar
• Kusuhara S, Fukushima Y, Ogura S, Inoue N, Uemura A. Pathophysiology of diabetic retinopathy: the old and the new. Diabetes Metab J. 2018;42:364–376. doi:https://doi.org/10.4093/dmj.2018.0182.
   PubMed Web of Science ®Google Scholar
• Sun Y, Smith LEH. Retinal vasculature in development and diseases. Annu Rev Vis Sci. 2018;4:101–122. doi:https://doi.org/10.1146/annurev-vision-091517-034018.
   PubMed Web of Science ®Google Scholar
• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–136. doi:https://doi.org/10.1016/S0140-6736(09)62124-3.
   PubMed Web of Science ®Google Scholar
• Adamis AP, Aiello LP, D’Amato RA. Angiogenesis and ophthalmic disease. Angiogenesis. 1999;3:9–14. doi:https://doi.org/10.1023/a:1009071601454.
   PubMedGoogle Scholar
• Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19. doi:https://doi.org/10.3390/ijms19061816.
   Web of Science ®Google Scholar
• Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122:1375–1394. doi:https://doi.org/10.1016/j.ophtha.2015.03.024.
   PubMed Web of Science ®Google Scholar
• Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol. 1961;66:366–378. doi:https://doi.org/10.1001/archopht.1961.00960010368014.
   PubMed Web of Science ®Google Scholar
• Barouch FC, Miyamoto K, Allport JR, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci. 2000;41:1153–1158. https://www.ncbi.nlm.nih.gov/pubmed/10752954.
   PubMed Web of Science ®Google Scholar
• Chaurasia SS, Lim RR, Parikh BH, et al. The NLRP3 inflammasome may contribute to pathologic neovascularization in the advanced stages of diabetic retinopathy. Sci Rep. 2018;8:2847. doi:https://doi.org/10.1038/s41598-018-21198-z.
   PubMed Web of Science ®Google Scholar
• Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17:611–625. doi:https://doi.org/10.1038/nrm.2016.87.
   PubMed Web of Science ®Google Scholar
• Kinnunen K, Piippo N, Loukovaara S, Hytti M, Kaarniranta K, Kauppinen A. Lysosomal destabilization activates the NLRP3 inflammasome in human umbilical vein endothelial cells (JHUVECs) cell commun. Signal. 2017;11:275–279. doi:https://doi.org/10.1007/s12079-017-0396-4.
   Google Scholar
• Hu L, Yang H, Ai M, Jiang S. Inhibition of TLR4 alleviates the inflammation and apoptosis of retinal ganglion cells in high glucose. Graefes Arch Clin Exp Ophthalmol. 2017;255:2199–2210. doi:https://doi.org/10.1007/s00417-017-3772-0.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–1203. doi:https://doi.org/10.1056/NEJMoa1414264.
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–161. doi:https://doi.org/10.1016/j.ophtha.2013.08.015.
   PubMed Web of Science ®Google Scholar
• Ogata N, Tombran-Tink J, Jo N, Mrazek D, Matsumura M. Upregulation of pigment epithelium-derived factor after laser photocoagulation. Am J Ophthalmol. 2001;132:427–429. doi:https://doi.org/10.1016/s0002-9394(01)01021-2.
   PubMed Web of Science ®Google Scholar
• Arnarsson A, Stefánsson E. Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 2000;41:877–879. https://www.ncbi.nlm.nih.gov/pubmed/10711707.
   PubMed Web of Science ®Google Scholar
• Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125:1608–1622. doi:https://doi.org/10.1016/j.ophtha.2018.04.007.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626–635.e2. doi:https://doi.org/10.1016/j.ophtha.2010.12.028.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–1077.e35. doi:https://doi.org/10.1016/j.ophtha.2010.02.031.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10:128. doi:https://doi.org/10.1038/s41419-019-1413-8.
   PubMed Web of Science ®Google Scholar
• Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10:210–215. doi:https://doi.org/10.1038/nri2725.
   PubMed Web of Science ®Google Scholar
• Maslanik T, Mahaffey L, Tannura K, Beninson L, Greenwood BN, Fleshner M. The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stressor exposure. Brain Behav Immun. 2013;28:54–62. doi:https://doi.org/10.1016/j.bbi.2012.10.014.
   PubMed Web of Science ®Google Scholar
• Savage CD, Lopez-Castejon G, Denes A, Brough D. NLRP3-inflammasome activating DAMPs stimulate an inflammatory response in Glia in the absence of priming which contributes to brain inflammation after injury. Front Immunol. 2012;3:288. doi:https://doi.org/10.3389/fimmu.2012.00288.
   PubMed Web of Science ®Google Scholar
• Davis BK, Wen H, Ting JP-Y. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol. 2011;29:707–735. doi:https://doi.org/10.1146/annurev-immunol-031210-101405.
   PubMed Web of Science ®Google Scholar
• Yerramothu P, Vijay AK, Willcox MDP. Inflammasomes, the eye and anti-inflammasome therapy. Eye. 2018;32:491–505. doi:https://doi.org/10.1038/eye.2017.241.
   PubMed Web of Science ®Google Scholar
• Kim YK, Shin JS, Nahm MH. NOD-like receptors in infection, immunity, and diseases. Yonsei Med J. 2016;57:5–14. doi:https://doi.org/10.3349/ymj.2016.57.1.5.
   PubMed Web of Science ®Google Scholar
• Sepehri Z, Kiani Z, Afshari M, Kohan F, Dalvand A, Ghavami S. Inflammasomes and type 2 diabetes: an updated systematic review. Immunol Lett. 2017;192:97–103. doi:https://doi.org/10.1016/j.imlet.2017.10.010.
   PubMed Web of Science ®Google Scholar
• Hornung V, Latz E. Critical functions of priming and lysosomal damage for NLRP3 activation. Eur J Immunol. 2010;40:620–623. doi:https://doi.org/10.1002/eji.200940185.
   PubMed Web of Science ®Google Scholar
• Jo E-K, Kim JK, Shin D-M, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Immunol. 2016;13:148–159.
   Web of Science ®Google Scholar
• Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia. 1996;39:1005–1029. https://link.springer.com/article/10.1007/BF00400649.
   PubMed Web of Science ®Google Scholar
• Lee H-M, Kim -J-J, Kim HJ, Shong M, Ku BJ, Jo E-K. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62:194–204. doi:https://doi.org/10.2337/db12-0420.
   PubMed Web of Science ®Google Scholar
• Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110:851–860. doi:https://doi.org/10.1172/JCI15318.
   PubMed Web of Science ®Google Scholar
• Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007;56:224–230. doi:https://doi.org/10.2337/db06-0427.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhao M, Zhao S, et al. Activation of the TXNIP/NLRP3 inflammasome pathway contributes to inflammation in diabetic retinopathy: a novel inhibitory effect of minocycline. Inflamm Res. 2017;66:157–166. doi:https://doi.org/10.1007/s00011-016-1002-6.
   PubMed Web of Science ®Google Scholar
• Lebreton F, Berishvili E, Parnaud G, et al. NLRP3 inflammasome is expressed and regulated in human islets. Cell Death Dis. 2018;9:726. doi:https://doi.org/10.1038/s41419-018-0764-x.
   PubMed Web of Science ®Google Scholar
• Loukovaara S, Piippo N, Kinnunen K, Hytti M, Kaarniranta K, Kauppinen A. NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy. Acta Ophthalmol. 2017;95:803–808. doi:https://doi.org/10.1111/aos.13427.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang X, Liao N, et al. Enhanced expression of NLRP3 inflammasome-related inflammation in diabetic retinopathy. Science. 2018;59:978–985. doi:https://doi.org/10.1167/iovs.17-22816.
   Web of Science ®Google Scholar
• Song Z, Sun M, Zhou F, Huang F, Qu J, Chen D. Increased intravitreous interleukin-18 correlated to vascular endothelial growth factor in patients with active proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2014;252:1229–1234. doi:https://doi.org/10.1007/s00417-014-2586-6.
   PubMed Web of Science ®Google Scholar
• Yin Y, Chen F, Wang W, Wang H, Zhang X. Resolvin D1 inhibits inflammatory response in STZ-induced diabetic retinopathy rats: possible involvement of NLRP3 inflammasome and NF-κB signaling pathway. Mol Vis. 2017;23:242–250. https://www.ncbi.nlm.nih.gov/pubmed/28465656.
   PubMed Web of Science ®Google Scholar
• Rivera JC, Sitaras N, Noueihed B, et al. Microglia and interleukin-1β in ischemic retinopathy elicit microvascular degeneration through neuronal semaphorin-3A. Arterioscler Thromb Vasc Biol. 2013;33:1881–1891. doi:https://doi.org/10.1161/ATVBAHA.113.301331.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang F, Zhang X, et al. Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation. Mol Cell Biochem. 2018;445:105–115. doi:https://doi.org/10.1007/s11010-017-3256-x.
   PubMed Web of Science ®Google Scholar
• Devi TS, Lee I, Hüttemann M, Kumar A, Nantwi KD, Singh LP. TXNIP links innate host defense mechanisms to oxidative stress and inflammation in retinal Muller glia under chronic hyperglycemia: implications for diabetic retinopathy. Exp Diabetes Res. 2012;2012:438238. doi:https://doi.org/10.1155/2012/438238.
   PubMedGoogle Scholar
• Shi H, Zhang Z, Wang X, et al. Inhibition of autophagy induces IL-1β release from ARPE-19 cells via ROS mediated NLRP3 inflammasome activation under high glucose stress. Biochem Biophys Res Commun. 2015;463:1071–1076. doi:https://doi.org/10.1016/j.bbrc.2015.06.060.
   PubMed Web of Science ®Google Scholar
• Liu J, Copland DA, Theodoropoulou S, et al. Impairing autophagy in retinal pigment epithelium leads to inflammasome activation and enhanced macrophage-mediated angiogenesis. Sci Rep. 2016;6:20639. doi:https://doi.org/10.1038/srep20639.
   PubMed Web of Science ®Google Scholar
• Gao J, Cui JZ, To E, Cao S, Matsubara JA. Evidence for the activation of pyroptotic and apoptotic pathways in RPE cells associated with NLRP3 inflammasome in the rodent eye. J Neuroinflammation. 2018;15:15. doi:https://doi.org/10.1186/s12974-018-1062-3.
   PubMed Web of Science ®Google Scholar
• Mugisho OO, Green CR, Kho DT, et al. The inflammasome pathway is amplified and perpetuated in an autocrine manner through connexin43 hemichannel mediated ATP release. Biochim Biophys Acta Gen Subj. 2018;1862:385–393. doi:https://doi.org/10.1016/j.bbagen.2017.11.015.
   PubMed Web of Science ®Google Scholar
• Muñoz-Planillo R, Kuffa P, Martínez-Colón G, Smith BL, Rajendiran TM, Núñez G. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013;38:1142–1153. doi:https://doi.org/10.1016/j.immuni.2013.05.016.
   PubMed Web of Science ®Google Scholar
• Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16:407–420. doi:https://doi.org/10.1038/nri.2016.58.
   PubMed Web of Science ®Google Scholar
• Mugisho OO, Green CR, Zhang J, Acosta ML, Rupenthal ID. Connexin43 hemichannels: a potential drug target for the treatment of diabetic retinopathy. Drug Discov Today. 2019;24:1627–1636. doi:https://doi.org/10.1016/j.drudis.2019.01.011.
   PubMed Web of Science ®Google Scholar
• Contreras JE, Sáez JC, Bukauskas FF, Bennett MVL. Gating and regulation of connexin 43 (Cx43) hemichannels. Proc Natl Acad Sci USA. 2003;100:11388–11393. doi:https://doi.org/10.1073/pnas.1434298100.
   PubMed Web of Science ®Google Scholar
• Giaume C, Leybaert L, Naus CC, Sáez JC. Connexin and pannexin hemichannels in brain glial cells: properties, pharmacology, and roles. Front Pharmacol. 2013;4. doi:https://doi.org/10.3389/fphar.2013.00088.
   Google Scholar
• Green CR, Nor MNM, Mugisho OO, Rupenthal ID, Squirrell DM, Acosta ML. Connexin hemichannel block shuts down inflammation in an animal model of chronic diabetic retinopathy to improve structural and functional outcomes. Invest Ophthalmol Vis Sci. 2019;60:2784.
   Web of Science ®Google Scholar
• Wang S, Ji L-Y, Li L, Li J-M. Oxidative stress, autophagy and pyroptosis in the neovascularization of oxygen-induced retinopathy in mice. Mol Med Rep. 2019;19:927–934. doi:https://doi.org/10.3892/mmr.2018.9759.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang L, Pitzer AL, Li X, P-L L, Zhang Y. Contribution of redox-dependent activation of endothelial NLRP3 inflammasomes to hyperglycemia-induced endothelial dysfunction. J Mol Med. 2016;94:1335–1347. doi:https://doi.org/10.1007/s00109-016-1481-5.
   PubMed Web of Science ®Google Scholar
• Calderon GD, Juarez OH, Hernandez GE, Punzo SM, De la Cruz ZD. Oxidative stress and diabetic retinopathy: development and treatment. Eye. 2017;31:1122–1130. doi:https://doi.org/10.1038/eye.2017.64.
   PubMed Web of Science ®Google Scholar
• Nakahira K, Haspel JA, Rathinam VAK, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12:222–230. doi:https://doi.org/10.1038/ni.1980.
   PubMed Web of Science ®Google Scholar
• Kumar A, Mittal R. Mapping Txnip: key connexions in progression of diabetic nephropathy. Pharmacol Rep. 2018;70:614–622. doi:https://doi.org/10.1016/j.pharep.2017.12.008.
   PubMed Web of Science ®Google Scholar
• Hwang J, Suh H-W, Jeon YH, et al. The structural basis for the negative regulation of thioredoxin by thioredoxin-interacting protein. Nat Commun. 2014;5:2958. doi:https://doi.org/10.1038/ncomms3958.
   PubMed Web of Science ®Google Scholar
• Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11:136–140. doi:https://doi.org/10.1038/ni.1831.
   PubMed Web of Science ®Google Scholar
• Singh LP, Devi TS, Yumnamcha T. The role of txnip in mitophagy dysregulation and inflammasome activation in diabetic retinopathy: a new perspective. JOJ Ophthalmol. 2017;4. doi:https://doi.org/10.19080/jojo.2017.04.555643.
   Google Scholar
• Perrone L, Devi TS, Hosoya K-I, Terasaki T, Singh LP. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis. 2010;1:e65. doi:https://doi.org/10.1038/cddis.2010.42.
   PubMed Web of Science ®Google Scholar
• Shalev A. Minireview: thioredoxin-interacting protein: regulation and function in the pancreatic β-celll. Mo Endocrinol. 2014;28:1211–1220. doi:https://doi.org/10.1210/me.2014-1095.
   PubMed Web of Science ®Google Scholar
• El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205:2409–2417. doi:https://doi.org/10.1084/jem.20081188.
   PubMed Web of Science ®Google Scholar
• Devi TS, Somayajulu M, Kowluru RA, Singh LP. TXNIP regulates mitophagy in retinal Müller cells under high-glucose conditions: implications for diabetic retinopathy. Cell Death Dis. 2017;8:e2777. doi:https://doi.org/10.1038/cddis.2017.190.
   PubMed Web of Science ®Google Scholar
• Okada M, Matsuzawa A, Yoshimura A, Ichijo H. The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J Biol Chem. 2014;289:32926–32936. doi:https://doi.org/10.1074/jbc.M114.579961.
   PubMed Web of Science ®Google Scholar
• Piippo N, Korkmaz A, Hytti M, et al. Decline in cellular clearance systems induces inflammasome signaling in human ARPE-19 cells. Biochim Biophys Acta. 2014;1843:3038–3046. doi:https://doi.org/10.1016/j.bbamcr.2014.09.015.
   PubMed Web of Science ®Google Scholar
• Thounaojam MC, Montemari A, Powell FL, et al. Monosodium urate contributes to retinal inflammation and progression of diabetic retinopathy. Diabetes. 2019;68:1014–1025. doi:https://doi.org/10.2337/db18-0912.
   PubMed Web of Science ®Google Scholar
• Gao J, Liu RT, Cao S, et al. NLRP3 inflammasome: activation and regulation in age-related macular degeneration. Mediators Inflamm. 2015;2015:690243. doi:https://doi.org/10.1155/2015/690243.
   PubMed Web of Science ®Google Scholar
• Kono H, Chen C-J, Ontiveros F, Rock KL. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest. 2010;120:1939–1949. doi:https://doi.org/10.1172/JCI40124.
   PubMed Web of Science ®Google Scholar
• Schoenberger SD, Kim SJ, Sheng J, Rezaei KA, Lalezary M, Cherney E. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Inv Ophthalmol Visual Sci. 2012;53:5906–5911. doi:https://doi.org/10.1167/iovs.12-10410.
   PubMed Web of Science ®Google Scholar
• Schütt F, Bergmann M, Holz FG, Kopitz J. Isolation of intact lysosomes from human RPE cells and effects of A2-E on the integrity of the lysosomal and other cellular membranes. Graefes Arch Clin Exp Ophthalmol. 2002;240:983–988.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tao J, Yao Y. Prostaglandin E2 activates NLRP3 inflammasome in endothelial cells to promote diabetic retinopathy. Horm Metab Res. 2018;50:704–710. doi:https://doi.org/10.1055/a-0664-0699.
   PubMed Web of Science ®Google Scholar
• Wang M, Wang Y, Xie T, et al. Prostaglandin E2/EP2 receptor signalling pathway promotes diabetic retinopathy in a rat model of diabetes. Diabetologia. 2019;62:335–348. doi:https://doi.org/10.1007/s00125-018-4755-3.
   PubMed Web of Science ®Google Scholar
• Johnson EI, Dunlop ME, Larkins RG. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Curr Eye Res. 1999;18:79–82. doi:https://doi.org/10.1076/ceyr.18.2.79.5386.
   PubMed Web of Science ®Google Scholar
• Yanni SE, Barnett JM, Clark ML, Penn JS. The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Invest Ophthalmol Vis Sci. 2009;50:5479–5486. doi:https://doi.org/10.1167/iovs.09-3652.
   PubMed Web of Science ®Google Scholar
• Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. Invest Ophthalmol Vis Sci. 1998;39:581–591. https://www.ncbi.nlm.nih.gov/pubmed/9501870.
   PubMed Web of Science ®Google Scholar
• Shen J, Choy DF, Yoshida T, et al. Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF. J Cell Physiol. 2014;229:974–983. doi:https://doi.org/10.1002/jcp.24575.
   PubMed Web of Science ®Google Scholar
• Hirano Y, Yasuma T, Mizutani T, et al. IL-18 is not therapeutic for neovascular age-related macular degeneration. Nat Med. 2014;20:1372–1375. doi:https://doi.org/10.1038/nm.3671.
   PubMed Web of Science ®Google Scholar
• Di Virgilio F. The therapeutic potential of modifying inflammasomes and NOD-like receptors. Pharmacol Rev. 2013;65:872–905. doi:https://doi.org/10.1124/pr.112.006171.
   PubMed Web of Science ®Google Scholar
• Ildefonso CJ, Jaime H, Rahman MM, et al. Gene delivery of a viral anti-inflammatory protein to combat ocular inflammation. Hum Gene Ther. 2015;26:59–68.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Tosi GM, et al. The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. Clin Rheumatol. 2017;36:2307–2318. doi:https://doi.org/10.1007/s10067-016-3527-z.
   PubMed Web of Science ®Google Scholar
• Johnston JB, Barrett JW, Nazarian SH, et al. A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity. 2005;23:587–598. doi:https://doi.org/10.1016/j.immuni.2005.10.003.
   PubMed Web of Science ®Google Scholar
• Shi H, Wang Y, Li X, et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat Immunol. 2016;17:250–258. doi:https://doi.org/10.1038/ni.3333.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lv X, Hu Z, et al. Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction. Cell Death Dis. 2017;8:e2941. doi:https://doi.org/10.1038/cddis.2017.308.
   PubMed Web of Science ®Google Scholar
• Coll RC, Robertson AAB, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21:248–255. doi:https://doi.org/10.1038/nm.3806.
   PubMed Web of Science ®Google Scholar
• Zhai Y, Meng X, Ye T, Xie W, Sun G, Sun X. Inhibiting the NLRP3 inflammasome activation with MCC950 ameliorates diabetic encephalopathy in db/db mice. Molecules. 2018;23. doi:https://doi.org/10.3390/molecules23030522.
   Google Scholar
• Hill JR, Coll RC, Sue N, et al. Sulfonylureas as concomitant insulin secretagogues and NLRP3 inflammasome inhibitors. ChemMedChem. 2017;12:1449–1457. doi:https://doi.org/10.1002/cmdc.201700270.
   PubMed Web of Science ®Google Scholar
• Berger EA, Carion TW, Jiang Y, et al. β-adrenergic receptor agonist, compound 49b, inhibits TLR4 signaling pathway in diabetic retina. Immunol Cell Biol. 2016;94:656–661. doi:https://doi.org/10.1038/icb.2016.21.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Liu L, Steinle JJ. Compound 49b regulates ZO-1 and occludin levels in human retinal endothelial cells and in mouse retinal vasculature. Invest Ophthalmol Vis Sci. 2017;58:185–189. doi:https://doi.org/10.1167/iovs.16-20412.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Liu L, Curtiss E, Steinle JJ. Epac1 blocks NLRP3 inflammasome to reduce IL-1β in retinal endothelial cells and mouse retinal vasculature. Mediators Inflamm. 2017;2017:2860956. doi:https://doi.org/10.1155/2017/2860956.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Park SY, Baek SE, et al. HMGB1 increases IL-1β production in vascular smooth muscle cells via NLRP3 inflammasome. Front Physiol. 2018;9:313. doi:https://doi.org/10.3389/fphys.2018.00313.
   PubMed Web of Science ®Google Scholar
• van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008;11:91–99. doi:https://doi.org/10.1007/s10456-008-9093-5.
   PubMed Web of Science ®Google Scholar
• Payne JF, Ray R, Watson DG, et al. Vitamin D insufficiency in diabetic retinopathy. Endocr Pract. 2012;18:185–193. doi:https://doi.org/10.4158/EP11147.OR.
   PubMed Web of Science ®Google Scholar
• Lu L, Lu Q, Chen W, Li J, Li C, Zheng Z. Vitamin D3 protects against diabetic retinopathy by inhibiting high-glucose-induced activation of the ROS/TXNIP/NLRP3 inflammasome pathway. J Diabetes Res. 2018;2018:8193523. doi:https://doi.org/10.1155/2018/8193523.
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Mohammad G, Santos JM, Tewari S, Zhong Q. Interleukin-1β and mitochondria damage, and the development of diabetic retinopathy. J Ocul Biol Dis Infor. 2011;4:3–9.
   PubMedGoogle Scholar
• Li S, Yang H, Chen X. Protective effects of sulforaphane on diabetic retinopathy: activation of the NRF2 pathway and inhibition of NLRP3 inflammasome formation. Exp Anim. 2019;68:221–231. doi:https://doi.org/10.1538/expanim.18-0146.
   PubMed Web of Science ®Google Scholar
• Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–1697. doi:https://doi.org/10.1016/S0140-6736(07)61607-9.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–244. doi:https://doi.org/10.1056/NEJMoa1001288.
   PubMed Web of Science ®Google Scholar
• Hao J, Zhang H, Yu J, Chen X, Yang L. Methylene blue attenuates diabetic retinopathy by inhibiting NLRP3 inflammasome activation in STZ-induced diabetic rats. Ocul Immunol Inflamm. 2019;27:836–843. doi:https://doi.org/10.1080/09273948.2018.1450516.
   PubMed Web of Science ®Google Scholar
• Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54:1559–1565. doi:https://doi.org/10.2337/diabetes.54.5.1559.
   PubMed Web of Science ®Google Scholar